Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for GRAIL, Inc. (GRAL : NSDQ)

• Company Description    GRAIL LLC is a biotechnology company. It focuses on developing technologies for early cancer detection. GRAIL LLC is based in Menlo Park, United States. Number of Employees: 1,000

• Price / Volume Information    Yesterday's Closing Price: $85.59 Daily Weekly Monthly 20 Day Moving Average: 709,750 shares Shares Outstanding: 38.98 (millions) Market Capitalization: $3,336.49 (millions) Beta: 4.52 52 Week High: $115.76 52 Week Low: $16.56 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.26% -18.12% 12 Week 20.33% 18.39% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1525 O`BRIEN DRIVE - MENLO PARK,CA 94025 USA ph: 833-694-2553 fax: - ir@grailbio.com https://grail.com

• General Corporate Information    Officers Robert Ragusa - Chief Executive Officer Gregory Summe - Chairperson of the Board Aaron Freidin - Chief Financial Officer William Chase - Director Steven Mizell - Director Peer Information GRAIL, Inc. (CORR.) GRAIL, Inc. (RSPI) GRAIL, Inc. (CGXP) GRAIL, Inc. (BGEN) GRAIL, Inc. (GTBP) GRAIL, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 384747101 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/19/26 Share - Related Items Shares Outstanding: 38.98 Most Recent Split Date: (:1) Beta: 4.52 Market Capitalization: $3,336.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.88 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-11.75 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.38 Price/Cash Flow: 2.97 Price / Sales: 23.52 EPS Growth vs. Year Ago Period: 37.56% vs. Previous Quarter: 22.64% Sales Growth vs. Year Ago Period: 26.32% vs. Previous Quarter: 1.83% ROE 12/31/25 - - 09/30/25 - -15.69 06/30/25 - -16.64 ROA 12/31/25 - - 09/30/25 - -13.35 06/30/25 - -14.02 Current Ratio 12/31/25 - - 09/30/25 - 7.61 06/30/25 - 9.23 Quick Ratio 12/31/25 - - 09/30/25 - 7.61 06/30/25 - 9.23 Operating Margin 12/31/25 - - 09/30/25 - -262.04 06/30/25 - -304.09 Net Margin 12/31/25 - - 09/30/25 - -286.43 06/30/25 - -329.86 Pre-Tax Margin 12/31/25 - - 09/30/25 - -384.26 06/30/25 - -445.82 Book Value 12/31/25 - - 09/30/25 - 62.14 06/30/25 - 64.34 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©